Clear the Pathway to What's Possible With DUAKLIR
The twice-daily dosing of Duaklir® Pressair® provides your patients with improved lung function in the morning and evening, which may help them rediscover their ability to do normal, everyday activities, all day long.2
Give every breath potential with DUAKLIR PRESSAIR.
Your Patients Don’t Have to Settle for a Diminished Quality of Life Due to COPD
DUAKLIR is an effective LAMA/LABA medication that improves breathing and has demonstrated improvement in quality of life as measured by St. George's Respiratory Questionnaire (SGRQ).4
The SGRQ is a patient-reported, respiratory disease-specific instrument designed to measure:5
Achieved clinically meaningful improvement* in health-related quality of life for patients taking DUAKLIR vs placebo.6
The SGRQ responder†‡ rate at week 24 for DUAKLIR was 58% compared to 39% with placebo odds ratio of 2.3 (95% Cl: 1.4, 3.6).
*Defined as a ≥4-unit improvement from baseline.
†DUAKLIR vs placebo did not meet statistical significance in two other phase 3 clinical trials.
‡A pooled analysis of ACLIFORM and AUGMENT.
*Benefits are defined as improvement in lung function of one bronchodilator vs two bronchodilators
†DUAKLIR is not indicated for the initial treatment of acute episodes of bronchospasm and does not replace the use of rescue inhalers.
COPD Is an Around-the-Clock Symptomatic Disease
Despite regular treatment, over 90% of patients with stable COPD experience symptoms at some point during the day, with the most troublesome times of the day being early morning and nighttime.7
Nighttime symptoms or awakenings
Shortness of breath
Defeated in how COPD has affected their daily lives and the activities they used to do
Helpless as their sphere of activities continues to shrink due to COPD